Equity
-€187,834
Debts exceed assets in financial year 2025.
OMNIPHAR
Lifetime
20 annual accounts with figures on one time axispeak €169,017 (2016)
€153,274▲ 34.5%
lowest -€95,187 (2021)
-€38,387▲ €19,818
peak €178,049 (2013)
-€187,834▼ €38,387
€556,906▲ 1.4%
peak 2 FTE (2022)
-not published
Board2 names since 2017
2 directorsECZANE and 1 other
Owners
100%Eczane
Documentsfilings and deeds
31-07-2026on the last day
2025micro format
Gross margin from €113,945 to €153,274Loss of €38,387Equity from -€149,448 to -€187,834
Key points
from the 2025 annual accountsLosses
-€304,075 in six years
Every financial year from 2020 to 2025 closed with a loss. 2021 was the heaviest.
Turnover
≈ €460,000 estimated
The accounts state no turnover.
Debts
€556,906 151% of the balance sheet
Financial debts 34%Suppliers 3%Taxes and wages 6%Other 56%
Of this, €365,823 falls due within a year.
Board
1 left
A director left. Latest change 01-01-2026 · 1 in office.
Position in the sector
-€187,834
Less equity than 95% of companies in retail trade. Sector median €41,015 · 22,952 companies.
Checked score
53
Fair
Financially stronger than 14% of micro companies in retail trade (NACE 47)
Probability in this band: 1.5% to 4.2%
Negative equity caps the score at 59.
Bankruptcy probability within 12 months
1.3% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,271 companies (NACE 47, micro).
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 3.8%
01-2025: 3.8%● unchanged vs 12-2024
02-2025: 3.9%▲ +0.1 percentage points vs 01-2025
03-2025: 3.9%● unchanged vs 02-2025
04-2025: 3.9%● unchanged vs 03-2025
05-2025: 3.7%▼ -0.2 percentage points vs 04-2025
06-2025: 3.6%▼ -0.1 percentage points vs 05-2025
07-2025: 3.8%▲ +0.2 percentage points vs 06-2025
08-2025: 4.6%▲ +0.8 percentage points vs 07-2025highest value
09-2025: 4.6%● unchanged vs 08-2025highest value
10-2025: 4.6%● unchanged vs 09-2025highest value
11-2025: 4.6%● unchanged vs 10-2025highest value
12-2025: 4.6%● unchanged vs 11-2025highest value
01-2026: 4.6%● unchanged vs 12-2025highest value
02-2026: 4.6%● unchanged vs 01-2026highest value
03-2026: 4.4%▼ -0.2 percentage points vs 02-2026
04-2026: 4.5%▲ +0.1 percentage points vs 03-2026
05-2026: 4.4%▼ -0.1 percentage points vs 04-2026
06-2026: 4.2%▼ -0.2 percentage points vs 05-2026
07-2026: 4.3%▲ +0.1 percentage points vs 06-2026
08-2026: 1.3%▼ -3.0 percentage points vs 07-2026lowest value
09-2026: 1.3%● unchanged vs 08-2026lowest value
10-2026: 1.3%● unchanged vs 09-2026lowest value
11-2026: 1.3%● unchanged vs 10-2026lowest value
Financial strengthWeak
Score breakdown
raises risk
Capped at 59: negative equity
Negative equity -€187,834
Loss of €38,387, the second in a row (financial year 2025)
Sector: Retail trade (NACE 47)
lowers risk
Size: total assets €369,071
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 6% of them on solvency, 16% on liquidity, 15% on profitability and 17% on growth.
The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 6,619 companies had the same profile as OMNIPHAR has now. Each dot stands for 17 companies, two years later.
84.5%
were still trading
10.0%
stopped another way
4.5%
went bankrupt
Another 1.0% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of OMNIPHAR itself: 1.3% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,619 companies, not a prediction for OMNIPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
No credit on open account
Liquidity is insufficient, with a current ratio of 0.8 (0.85 in 2024), below 1. Short-term debt is 99.1% and cash 13.8% of total assets. Equity is negative.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year -€187,834
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-07-2026, 0 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
on the day
2024
6 days early
2023
28 days late
2022
7 days early
2021
23 days early
2020
37 days early
2019
64 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 16 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 25 July (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
New managing director
ECZANE appointed, Virginie Lauwers resigned · Director discharge: Virginie Lauwers · General meeting of 01-01-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0880522349
2 directors appointed
ECZANE and Lauwers Virginie · Permanent representative: Lauwers Patrick · General meeting of 25-11-2022 · Gazette deed
Permanent representatives: Patrick Lauwers and Katty Vandekerkhove
Board meeting of 29-03-2021 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| OMNIPHAR Ronse | €369,071 | €153,274 | -50.9% | - |
| Apotheek Van Wambeke Temse | €391,356 | €155,445 | 23.6% | 1.7 |
| PHARMACIE DES PAGODES Genappe | €383,064 | €152,066 | 3.0% | 1.6 |
| PHARMACIE DERASSE La Louvière | €387,571 | €148,815 | 26.6% | 1.8 |
| APOTHEEK OLIVIA VAN MARCKE Kortrijk | €393,155 | €139,410 | 41.2% | - |
| Pharmacie DEMANET Ciney | €331,843 | €152,025 | -13.2% | - |
| APOTHEEK JULIE BORGHIJS Aartselaar | €398,069 | €140,668 | 9.5% | 1 |
These companies have the same main activity as OMNIPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €332,000 and €398,000, founded between 2004 and 2007.
Official details
Source: KBO- Status
- Active since 05-04-2006Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.152.834.7279600 Ronse, since 11-04-2006
- Financial year end
- 31 December
- Peppol
- Reachable since 24-11-2023
Annual accounts 2025
- €369,071▼ 7.7%
- Employeeson 31-12-2025
- 2=
- Filing
- Filed on 31-07-2026, on the last day of the filing period
Insights on OMNIPHAR
OMNIPHAR files the micro format. That format states no turnover. The gross margin rose from €110,382 in 2006 to €153,274 in 2025.
The balance sheet grew most from 2018 to 2020 through fixed assets.
Eczane holds all the shares. In April 2026, the Official Gazette published the appointment of ECZANE as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about OMNIPHAR
- What is the company number of OMNIPHAR?
- The company number of OMNIPHAR is 0880.522.349. The VAT number is the same number with BE in front: BE 0880.522.349.
- Where is OMNIPHAR based?
- The registered office is at Oswald Ponettestraat 42, 9600 Ronse.Company details
- What does OMNIPHAR do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of OMNIPHAR?
- OMNIPHAR is a private limited company (BV).
- When was OMNIPHAR founded?
- OMNIPHAR was founded on 05-04-2006.
- Is OMNIPHAR still active?
- Yes, OMNIPHAR is an active enterprise in the KBO register.
- How many employees does OMNIPHAR have?
- OMNIPHAR had an average of 2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does OMNIPHAR fall under?
- In its 2025 annual accounts, OMNIPHAR states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of OMNIPHAR?
- The turnover in financial year 2025 is ≈ €460,000. This figure is estimated from the gross margin of €153,274 and 31 comparable companies (NACE 477). It probably lies between €330,000 and €870,000.
- Is OMNIPHAR profitable?
- In financial year 2025, OMNIPHAR made a loss of €38,387.
- Where can I find the annual accounts of OMNIPHAR?
- OMNIPHAR filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of OMNIPHAR due?
- OMNIPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.